Fig 1.
*Tumor was identified by cervical ultrasonogram. AE, adverse event.
Fig 2.
The area enclosed by the dotted line indicates the double-blind treatment phase. *Patients with prior cinacalcet treatment.
Table 1.
Baseline demographic and clinical characteristics of patients in the five groups (Safety analysis set).
Fig 3.
Point estimate of percent changes in iPTH at EOT.
The error bars indicate standard deviation. iPTH, intact parathyroid hormone; EOT, end of treatment; CI, confidence interval.
Fig 4.
Contrast patterns used for the dose-response profile of evocalcet.
The dose-response profile was examined using seven types of contrast patterns involving the respective mean values in the evocalcet 0.5, 1, and 2 mg and placebo groups. The contrast coefficients are displayed on the y-axis of each graph.
Table 2.
Dose-response profile (contrast patterns).
Fig 5.
Time-course profile of iPTH (A) and percent change from baseline (B). iPTH, intact parathyroid hormone.
Fig 6.
Time-course profiles of clinical laboratory variables (secondary endpoints).
(A) whole PTH; (B) corrected calcium; (C) ionized calcium; (D) phosphorus; (E) intact FGF23; and (F) corrected calcium-phosphorus product. PTH, parathyroid hormone; FGF23, fibroblast growth factor 23.
Table 3.
Summary of gastrointestinal adverse events and calcium decrease-related events.